Galectin Therapeutics (NASDAQ:GALT) Raised to “Buy” at Zacks Investment Research – Riverton Roll
Galectin Therapeutics (NASDAQ:GALT) Raised to “Buy” at Zacks Investment Research Riverton Roll
Zacks Investment Research upgraded shares of Galectin Therapeutics (NASDAQ:GALT) from a hold rating to a buy rating in a research note released on …
Source: Investment New Feed